Register Login

All Posts

September 2024 Quick Question: PTT

I (Geo) prefer PTT to APTT or aPTT because the “A” or “a” is superfluous.  Laboratory scientists no longer offer an “unactivated” PTT. The “partial thromboplastin” reagent consists of a phospholipid or combination of phospholipids that may include animal, plant, or synthetic sourced phosphatidylserine, phosphatidylcholine, phosphatidylinositol, sphingomyelin, and/or phosphatidylethanolamine. Accompanying the phospholipid is one of […]
read more

August 2024 Quick Question Summary: Rebalancing Therapy

Our August 2024 Quick Question, which attracted 18 responses, asked, “Which hemophilia ‘rebalancing’ therapy suppresses antithrombin RNA production?” Here are your answers: Efanesoctocog alfa: 0 Concizumab: 3 (17%) Octavian 2 (11%) Hemgenix 3 (17%) Fitusiran 10 (55%) Rebalancing therapy is the name for using RNA inhibitors (RNAi) that suppress mRNA synthesis, subsequently suppressing selected molecules. […]
read more

Extended Life Cryoprecipitate Fibrinogen

As reported by Amy Carpenter quoting Jay Hudgins, DO, MS, director of hemostasis and thrombosis, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio, USA in the August 2024 edition of CAP Today, extended-life cryoprecipitate has several applications. INTERCEPT®, is the Cerus, Inc. trademark for their materials that crosslink and inactivate bacterial and […]
read more

A Molecular Approach to Assess Platelet Hyperreactivity

Friend Ed Groenendal forwarded this UPI summary of a molecular approach correlating evidence of hyperresponsive platelets to major adverse cardiac or limb events. The investigators started with aggregometry-defined platelet hyperreactivity to apply a transcriptome-based platelet reactivity expression score (PRESS). Click below to see the detailed open-access article describing the development and application of the PRESS. […]
read more

August 2024 Quick Question: Hemophilia Treatment

Several hemophilia A or B treatments are in development or have been approved since 2021. Among these are the “rebalancing” preparations that suppress control proteins such as tissue factor pathway inhibitor (TFPI), antithrombin (AT), or activated protein C (APC). Rebalancing preparations are designed to compensate for the bleeding tendencies in FVIII or FIX deficiency without […]
read more